Mayo's plasma program shows first signs of COVID-19 benefit
August 6, 2020
Preliminary research by Mayo Clinic shows that high-dose plasma therapy is correlated with fewer deaths in patients with severe COVID-19.
A 10 percentage point difference in deaths was found when comparing hospitalized COVID-19 patients who received donor plasma with high concentrations of virus-fighting antibodies compared with those who received lower concentrations, Mayo reported.
The findings are good news in the fight against a global pandemic with few proven treatments and an infectious disease that as of Wednesday had caused 57,779 known infections and 1,629 deaths in the state, according to the Minnesota Department of Health.